Gastroenterology Section, Perugia General Hospital, San Sisto (Perugia) 06156, Italy.
Pathology Unit, ASST Spedali Civili, Brescia 25100, Italy.
World J Gastroenterol. 2018 Dec 21;24(47):5322-5330. doi: 10.3748/wjg.v24.i47.5322.
Ulcerative colitis (UC), a chronic, relapsing, remitting disease of the colon and rectum, is characterized by inflammatory ulceration of the mucosa. Current UC therapy relies on controlling acute episodes and preventing relapse. To predict modifications in the natural course of UC, mucosal healing (MH) has emerged as a major treatment goal. Endoscopic evaluation is considered the gold standard for assessing MH, which can be achieved by conventional drugs and biologics in many, but not all, patients. Consequently, interest is focusing on the development of new substances for UC therapy, and new oral agents are in the pipeline. This review will focus on the ability of newly developed oral drugs to induce and maintain MH in UC patients.
溃疡性结肠炎（UC）是一种累及结肠和直肠的慢性、反复发作、缓解的疾病，其特征为黏膜炎症性溃疡。目前的 UC 治疗依赖于控制急性发作和预防复发。为了预测 UC 的自然病程变化，黏膜愈合（MH）已成为一个主要的治疗目标。内镜评估被认为是评估 MH 的金标准，在许多（但不是全部）患者中，常规药物和生物制剂可以实现 MH。因此，人们对开发用于 UC 治疗的新物质的兴趣越来越大，新的口服药物也在研发中。本综述将重点关注新开发的口服药物在 UC 患者中诱导和维持 MH 的能力。
